Sign in Subscribe

Vertex Faces Pain Drug Setbacks Amidst Q2 Earnings Beat

Vertex Pharmaceuticals' stock fell after its pain drug VX-993 failed a trial. Despite this, Q2 earnings exceeded estimates, driven by cystic fibrosis drugs. Journavx also faces FDA limitations.

Vertex Faces Pain Drug Setbacks Amidst Q2 Earnings Beat
Credit: Vertex Pharmaceuticals

This post is for paying subscribers only

Already have an account? Sign in.